Trials / Completed
CompletedNCT01973023
Stroke's Gait Pattern Modifications of Induced by Repeated BTI
Improvement of Chronic Stroke Patients Gait Pattern Following Repetitive Multifocal Botulinum Toxin Injection Sessions in Paretic Lower Limb: an Observational Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 25 (actual)
- Sponsor
- Centre d'Investigation Clinique et Technologique 805 · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chronic stroke patients exhibit gait pattern alterations which are mainly due to spasticity and treated with repetitive multifocal botulinum toxin injection(BTI). Several studies demonstrated that single BTI-session in a single muscle of paretic lower limb(LL) improved kinematic gait parameters(GP) but surprisingly none of them assessed the effects of repetitive multifocal BTI on patient's gait pattern and their duration. The aim was to evaluate the impact of repetitive multifocal BTI-sessions on GP of chronic stroke patients. To that end, gait of patients has been compared using 3D-gait analysis after at least 2 consecutive BTI sessions.
Detailed description
All the patients will be tretaed with BTI . these injections will be performed under electrical stimulation control (\~5mA). The dose, the number of site of injection per muscle is at the discretion of the physician according to patients' needs and physicians' routine clinical practice. The dilution the most commonly used will depend on the type of BoNT-A (BOTOX®, XEOMIN® or DYSPORT®) and was 100 U for 2.5ml (BOTOX® and XEOMIN®) or 500 U for 2.5 ml (Dysport®).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Motion analysis | Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2013-10-01
- Completion
- 2014-01-01
- First posted
- 2013-10-31
- Last updated
- 2016-03-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01973023. Inclusion in this directory is not an endorsement.